OP05 Primary efficacy and safety of mirikizumab in moderate to severe Crohns Disease: results of the treat-through VIVID 1 study

Research output: Contribution to journal › Article › peer-review

Original language	English
Journal	Journal of Crohn's and Colitis
DOIs	https://doi.org/10.1093/ecco-jcc/jjad212.0005
Publication status	Published - 2024

Keywords

@article{cb7a6e93206144ce9f329337ad777015,

title = "OP05 Primary efficacy and safety of mirikizumab in moderate to severe Crohns Disease: results of the treat-through VIVID 1 study",

keywords = "Crohn's disease, Medicine, Disease, Intensive care medicine, Internal medicine",

author = "Subrata Ghosh",

year = "2024",

doi = "10.1093/ecco-jcc/jjad212.0005",

language = "English",

journal = "Journal of Crohn's and Colitis",

issn = "1873-9946",

publisher = "Oxford University Press",

}

TY - JOUR

T1 - OP05 Primary efficacy and safety of mirikizumab in moderate to severe Crohns Disease: results of the treat-through VIVID 1 study

AU - Ghosh, Subrata

PY - 2024

Y1 - 2024

KW - Crohn's disease

KW - Medicine

KW - Disease

KW - Intensive care medicine

KW - Internal medicine

U2 - 10.1093/ecco-jcc/jjad212.0005

DO - 10.1093/ecco-jcc/jjad212.0005

M3 - Article

SN - 1873-9946

JO - Journal of Crohn's and Colitis

JF - Journal of Crohn's and Colitis

ER -